FDA approves GSK and Theravance COPD drug

Share this article:

US regulators approved Anoro Ellipta, an inhaled lung drug treatment for use in COPD. The drug—developed in tandem by Glaxo and Theravance—carries a black box warning for an increased risk of asthma-related death. In September, an advisory panel endorsed the drug 11-2. Analysts forecast annual sales of Anoro Ellipta at $2.65 billion by 2018, according to Thomson Reuters.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.